Fragile X syndrome and targeted treatment trials
R Hagerman, J Lauterborn, J Au… - Modeling fragile X …, 2012 - Springer
Work in recent years has revealed an abundance of possible new treatment targets for
fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse …
fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse …
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
C Santiskulvong, GE Konecny, M Fekete… - Clinical Cancer …, 2011 - AACR
Purpose: This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-
BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy …
BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy …
Mechanisms of resistance to mTOR inhibitors
L Formisano, F Napolitano, R Rosa, V D'Amato… - Critical reviews in …, 2020 - Elsevier
In several tumors the PI3K/AKT/mTOR pathway is frequently disrupted, an event that results
in uncontrolled cell proliferation and tumor growth. Through the years, several compounds …
in uncontrolled cell proliferation and tumor growth. Through the years, several compounds …
[PDF][PDF] Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
CS Mitsiades, FE Davies, JP Laubach… - Journal of clinical …, 2011 - academia.edu
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
HJ Choi, JH Heo, JY Park, JY Jeong, HJ Cho… - Gynecologic …, 2019 - Elsevier
Objective Ovarian cancer is the leading cause of gynecologic-related mortality worldwide.
Despite successful initial treatment, overall survival rates are very low because tumors …
Despite successful initial treatment, overall survival rates are very low because tumors …
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
JC Montero, A Esparís-Ogando, MF Re-Louhau… - Oncogene, 2014 - nature.com
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …
response to chemotherapy, relapses are frequent and resistance to available treatments is …
[HTML][HTML] The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Purpose Bortezomib is an important agent in multiple myeloma treatment, but resistance in
cell lines and patients has been described. The main mechanisms of resistance described in …
cell lines and patients has been described. The main mechanisms of resistance described in …
Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication
GR Campbell, RS Bruckman, SD Herns, S Joshi… - Journal of Biological …, 2018 - ASBMB
In this study, we investigated the effects of the dual phosphatidylinositol 3-
kinase/mechanistic target of rapamycin (PI3K/MTOR) inhibitor dactolisib (NVP-BEZ235), the …
kinase/mechanistic target of rapamycin (PI3K/MTOR) inhibitor dactolisib (NVP-BEZ235), the …
The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin …
B Hoang, A Benavides, Y Shi, Y Yang, P Frost… - Journal of Biological …, 2012 - ASBMB
Activation of PI3-K-AKT and ERK pathways is a complication of mTOR inhibitor therapy.
Newer mTOR inhibitors (like pp242) can overcome feedback activation of AKT in multiple …
Newer mTOR inhibitors (like pp242) can overcome feedback activation of AKT in multiple …
The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing
R Diaz-Gonzalez, FM Kuhlmann… - PLoS neglected …, 2011 - journals.plos.org
Background Target repurposing utilizes knowledge of “druggable” targets obtained in one
organism and exploits this information to pursue new potential drug targets in other …
organism and exploits this information to pursue new potential drug targets in other …